Chairman Cassidy, Ranking Member Sanders, and Members of the Committee, thank you for inviting me to testify today. My remarks summarize the Congressional Budget Office's recent report about the 340B Drug Pricing Program. That report examines trends in drug purchases through the program from 2010 to 2021, the factors driving those trends, and the implications for the federal budget.
